Selected
Publications
This manuscript on Immatics’ lead TCR-T cell therapy, ACTengine® IMA203, features clinical and translational data from 40 heavily pretreated patients with solid tumors, including melanoma, mostly treated during the Phase 1a dose escalation part of the trial. Read more here.
In this commentary, Immatics, peer companies and non-profit institutions evaluate the current regulatory framework around HLA testing for T cell receptor-based therapeutics and propose adjustments that can improve the development of and access to TCR-based therapeutics. Read more here.
This publication co-authored by the University of Pennsylvania and Immatics highlights Immatics’ differentiated approach utilizing its target and TCR discovery platforms XPRESIDENT® and XCEPTOR® to develop a TCR-based cell therapy approach against COL6A3 exon 6, a novel, proprietary tumor stroma target. Read more here.
T cell receptor discovery for cancer and beyond: in this paper we identify novel SARS-CoV-2-specific TCRs against recently discovered epitopes demonstrating the versality of Immatics’ TCR discovery platform XCEPTOR®. Read more here.
Description of computational and experimental methods as part of the XPRESIDENT® technology platform that allow identification of true HLA ligands as targets for TCR-based immunotherapies by mass spectrometry.
Read more here.
Immatics scientists and collaborators present functionally empty and peptide-receptive HLA-A*02:01 molecules that enable quick generation of large libraries of peptide-MHC complexes for TCR screening. Read more here.
A review by two leaders of Immatics’ Cell Therapy CMC Group. Read more here.
Joint publication by MD Anderson Cancer Center and Immatics demonstrating the capability of Immatics to validate a new target class, RNA-edited pHLA targets. Read more here.
First publication on the GAPVAC actively personalized vaccine trial conducted by a consortium led by Immatics. The warehouse approach pioneered in GAPVAC was the blueprint for the ongoing ACTolog® clinical trial by Immatics, which applies the multi-target warehouse approach for the first time in ACT. Read more here.
First publication on the proprietary IMADetect® target biomarker screening platform by Immatics as used in all ongoing ACT trials. Immatics uses a unique approach setting the qPCR threshold for each target guided by XPRESIDENT® mass spectrometry. Read more here.
Demonstration of Immatics’ capabilities in a collaboration with Genentech to validate neoantigens. Read more here.
Application of the XPRESIDENT® platform on the therapeutic cancer vaccine IMA901. Development of IMA901 (and of all other cancer vaccines) has been discontinued. However, the paper demonstrates the outstanding capabilities to pioneer biomarker-driven clinical development – as also done in the ongoing Adoptive Cell Therapy (ACT) trials. Read more here.
The original paper by Toni Weinschenk, Co-founder and Chief Innovation Officer of Immatics on the XPRESIDENT® target discovery platform. Read more here.